Which are the clinical trial phase III of HER2 positive breast cancer ? 

Phase III clinical trials for HER2-positive breast cancer mentioned in the abstracts include: 1. Yang et al. conducted a phase III trial to evaluate the efficacy of non-cross-resistant adjuvant chemotherapy in patients with HR+/HER2-/LN+ breast cancer who were non-responsive to primary chemotherapy . 2. Patel et al. described a phase III trial (NCT05232916) investigating the addition of GP2 therapy to trastuzumab-based therapy as maintenance treatment for HER2-positive breast cancer . 3. Hamilton et al. presented the HER2CLIMB-05 trial, a phase III study evaluating the addition of tucatinib to standard of care (SOC) as maintenance therapy for HER2-positive metastatic breast cancer . 4. Another phase III study, PHEDRA, assessed the addition of pyrotinib to trastuzumab and docetaxel in the neoadjuvant setting for HER2-positive early or locally advanced breast cancer . Please note that these are the clinical trials mentioned in the abstracts provided, and there may be other ongoing or completed phase III trials for HER2-positive breast cancer not mentioned here.

Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial

The clinical trial phase III mentioned in the paper is the PHEDRA trial, which evaluated neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer.

Abstract OT2-16-03: Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer (HER2CLIMB-05, trial in progress)

The clinical trial phase III for HER2 positive breast cancer mentioned in the paper is HER2CLIMB-05, which is evaluating tucatinib plus trastuzumab and pertuzumab as maintenance therapy.

Abstract CT065: Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer (HER2CLIMB-05, trial in progress)

The provided paper is about the phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer (HER2CLIMB-05, trial in progress). However, it does not provide information about other phase III clinical trials for HER2 positive breast cancer.

122TiP Phase III study to evaluate the efficacy and safety of GLSI-100 (GP2 + GM-CSF) in breast cancer patients with residual disease or high-risk PCR after both neo-adjuvant and postoperative adjuvant anti-HER2 therapy, Flamingo-01

The clinical trial phase III for HER2 positive breast cancer mentioned in the paper is the ###122TiP Phase III study to evaluate the efficacy and safety of GLSI-100 (GP2 + GM-CSF) in breast cancer patients with residual disease or high-risk PCR after both neo-adjuvant and postoperative adjuvant anti-HER2 therapy, Flamingo-01###.